Your Source for BioScience Venture Capital Data
  • OnBioVC NEWS:

    - OnBioVC Announces Beta Launch of Service
    - OnBioVC INDEX(TM) Updated thru DEC 2009
    - OnBioVC 2009 Year-in-Review, now available
    - OnBioVC 1Q10 Trend Analysis, coming soon
  • SEARCH THE OnBioVC DATABASE:

  • business strategy life science

Advanced Cardiac Therapeutics (Laguna Beach, CA) a development-stage electrophysiology and radiometry medical device company focused on energy delivery via catheters for cardiac ablation, closed a $5M Series b financing. Participants include NBGI Ventures.

Zyngenia (Rockville, MD) a pre-clinical stage biotherapeutics company focused on multi-specific antibodies for oncology and autoimmune disorders, closed a $10M Series A financing. Particpants include New Enterprise Associates.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

GlycoMimetics (Gaithersburg, MD) a clinical-stage small molecule glycobiology company focused on cancer, inflammation and infectious disease, closed a $38M Series C financing. Participants include Genzyme Ventures, New Enterprise Associates, Novartis Venture Fund, Anthem Capital Management and Alliance Technology Ventures.
A more detailed company profile recently appeared on Life Science Deal Flow [HERE].

Arginetix (Baltimore, MD) a preclinical-stage pharmaceutical company focused on the small molecule inhibition of arginase for pulmonary arterial hypertension, closed a $4.6M Series B financing. Participants include Quaker BioVentures, MedImmune Ventures, Red Abbey Venture Partners, Maryland Health Care Product Development Corp. and Acidophil.

Sleep Solutions (Glen Burnies, MD) a commercial-stage medical device and diagnostics company focused on obstructive sleep apnea, closed a $20M Series F financing. Participants include Quaker BioVentures, Johnson & Johnson Dev Corp., TPG Growth, MedVenture Associates, Emergent Ventures and Lava Ventures.

Profectus BioSciences (Baltimore, MD) a clinical-stage biopharmaceutical focused on the development of vaccines for chronic viral infections, closed a $5M Series C financing. Participants include Cross Atlantic Capital Partners.

Zephyr Technology (Annapolis, MD) a commercial-stage device company focused on real-time monitoring of human of physiological and biomechanical conditions, closed a $2M Series B financing. Participants include Motorola Ventures.

GetWellNetwork (Bethesda, MD) a commercial stage telemedicine provider of interactive patient care solutions, closed a $10M Series C financing. Participants include Johnson & Johnson Development Corp., Valhalla Partners, Grosvenor Funds, Point Judith Capital and Village Ventures.

Psyadon Pharmaceuticals (Germantown, MD) early-stage developer of glutamate transport modulation for CNS indications, closed a $8M Series A financing. Participants include New Enterprise Associates, Aberdare Ventures and Domain Associates.

Nexeon MedSystems (Charleston, WV) developer of a suite of cobalt alloy coronary and peripheral stents, closed a $24M Series A financing. Participants include SurModics and Guidant Corp.

« Previous Entries  

to top of page...